• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Onduo taps Glytec’s insulin therapy software as part of virtual diabetes clinic

November 29, 2017 By Sarah Faulkner

GlytecGlytec has inked a deal with Onduo to integrate the company’s Glucommander Outpatient insulin management software into Onduo’s virtual diabetes clinic.

Onduo, a joint venture of Sanofi (NYSE:SNY) and Verily, is reportedly working to develop a platform that brings together medical devices, software and support from healthcare experts to help people manage their Type II diabetes.

The platform is slated to launch as a pilot program for certain U.S.-based payers and providers in early-2018.

“Roughly half of 7.5 million people in the U.S. who use insulin to manage their diabetes are not reaching their treatment goals, and millions more who could benefit from insulin therapy either avoid it or discontinue it,” Glytec’s CMO, Dr. Andrew Rhinehart, said in prepared remarks. “Fixing this decades-old problem represents one of the greatest opportunities to improve the quality and cost of diabetes care.”

“Everyone responds to insulin differently, so the key to optimizing insulin therapy is to ensure that dosing is personalized, timely and accurate, which is exactly what Glucommander Outpatient helps providers achieve,” he added.

The company’s cloud-based insulin management software has been evaluated in multiple studies, Glytec touted. According to data from those studies, patients using Glucommander hit their glucose targets in an average of 12.5 days and experienced a 2.5% drop in A1C over a year-long period.

“We are very excited to partner with Onduo and play an important role in this integrated care solution,” Glytec’s president and CEO, Bob Leonard, said. “We firmly believe that this type of best-of-breed matrix approach — synthesizing the most essential and innovative technologies and services – will emerge as the most potent way to drive improvements in the quality, safety and cost of care for people living with diabetes.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Glytec, Onduo, Sanofi-Aventis, Verily

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS